SAB Biotherapeutics Inc. (SABS)
NASDAQ: SABS · Delayed Price · USD
5.25
-0.71 (-11.91%)
At close: Jan 26, 2022 4:00 PM
5.24
-0.01 (-0.25%)
After-hours:Jan 26, 2022 4:00 PM EST
Income Statement (Annual)
Millions USD. Fiscal year is Jan - Dec.
| Year | 2020 | 2019 |
|---|---|---|
| Revenue | 55.24 | 3.44 |
| Revenue Growth (YoY) | 1504.91% | - |
| Gross Profit | 55.24 | 3.44 |
| Selling, General & Admin | 6.77 | 4.1 |
| Research & Development | 27.91 | 8.02 |
| Operating Expenses | 34.68 | 12.12 |
| Operating Income | 20.56 | -8.67 |
| Interest Expense / Income | 0.47 | 0.43 |
| Other Expense / Income | -0.03 | -0.12 |
| Pretax Income | 20.12 | -8.99 |
| Net Income | 20.12 | -8.99 |
| Net Income Common | 20.12 | -8.99 |
| Shares Outstanding (Basic) | 35 | 35 |
| Shares Outstanding (Diluted) | 58 | 35 |
| Shares Change | 64.84% | - |
| EPS (Basic) | 0.37 | -0.26 |
| EPS (Diluted) | 0.35 | -0.26 |
| Free Cash Flow Per Share | -0.08 | -0.28 |
| Gross Margin | 100.00% | 100.00% |
| Operating Margin | 37.22% | -252.01% |
| Profit Margin | 36.42% | -261.09% |
| Free Cash Flow Margin | -4.92% | -285.41% |
| EBITDA | 21.14 | -8.23 |
| EBITDA Margin | 38.26% | -239.25% |
| EBIT | 20.59 | -8.56 |
| EBIT Margin | 37.27% | -248.64% |
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).